BRPI0515562A - métodos e composições para avaliação do prognóstico do cáncer de mama - Google Patents
métodos e composições para avaliação do prognóstico do cáncer de mamaInfo
- Publication number
- BRPI0515562A BRPI0515562A BRPI0515562-2A BRPI0515562A BRPI0515562A BR PI0515562 A BRPI0515562 A BR PI0515562A BR PI0515562 A BRPI0515562 A BR PI0515562A BR PI0515562 A BRPI0515562 A BR PI0515562A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- prognosis
- compositions
- breast cancer
- computer program
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
"MéTODOS E COMPOSIçõES PARA AVALIAçãO DO DIAGNóSTICO DO CáNCER DE MAMA". São fornecidos métodos e composições para avaliação do prognóstico de um paciente com câncer de mama, particularmente um paciente com câncer de mama em estágio inicial. Os métodos da invenção compreendem a detecção da expressão de pelo menos um, mais particularmente pelo menos dois biomarcadores em uma amostra corporal, em que a superexpressão do biomarcador ou uma combinação de bimarcadores é indicativa do prognóstico do câncer de mama. Em algumas modalidades, a amostra corporal é uma amostra de tecido mamário, particularmente uma amostra de tumor primário da mama. Os biomarcadores da invenção são proteínas e/ou genes cuja superexpressão é indicativa de um prognóstico bom ou ruim do câncer. Biomarcadores de interesse incluem proteínas e genes envolvidos na regulação do ciclo celular, replicação de DNA, transcrição, transdução de sinal, proliferação celular, invasão, proteólise ou metástase. Em alguns aspectos da invenção, a superexpressão de um biomarcador de interesse é detectada no nível protéico usando anticorpos específicos para o biomarcador ou no nível de ácido nucléico usando técnicas de hibridização de ácido nucléico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61196504P | 2004-09-22 | 2004-09-22 | |
US61207304P | 2004-09-22 | 2004-09-22 | |
PCT/US2005/034152 WO2006036788A2 (en) | 2004-09-22 | 2005-09-22 | Methods and compositions for evaluating breast cancer prognosis |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0515562A true BRPI0515562A (pt) | 2008-07-29 |
Family
ID=35695736
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515581-9A BRPI0515581A (pt) | 2004-09-22 | 2005-09-22 | métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer |
BRPI0515562-2A BRPI0515562A (pt) | 2004-09-22 | 2005-09-22 | métodos e composições para avaliação do prognóstico do cáncer de mama |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515581-9A BRPI0515581A (pt) | 2004-09-22 | 2005-09-22 | métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer |
Country Status (11)
Country | Link |
---|---|
US (3) | US20060063190A1 (pt) |
EP (2) | EP1800130B1 (pt) |
JP (2) | JP2008513032A (pt) |
KR (2) | KR20070061893A (pt) |
AT (1) | ATE520988T1 (pt) |
AU (2) | AU2005289728B2 (pt) |
BR (2) | BRPI0515581A (pt) |
CA (2) | CA2580937C (pt) |
IL (2) | IL182062A0 (pt) |
MX (1) | MX2007003502A (pt) |
WO (2) | WO2006036726A1 (pt) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8594410B2 (en) * | 2006-08-28 | 2013-11-26 | Definiens Ag | Context driven image mining to generate image-based biomarkers |
US20060003391A1 (en) * | 2003-08-11 | 2006-01-05 | Ring Brian Z | Reagents and methods for use in cancer diagnosis, classification and therapy |
US20050112622A1 (en) * | 2003-08-11 | 2005-05-26 | Ring Brian Z. | Reagents and methods for use in cancer diagnosis, classification and therapy |
US20080131916A1 (en) * | 2004-08-10 | 2008-06-05 | Ring Brian Z | Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy |
EP2027465A2 (en) | 2006-05-17 | 2009-02-25 | Cellumen, Inc. | Method for automated tissue analysis |
KR100786759B1 (ko) * | 2006-07-07 | 2007-12-18 | 김현기 | Hccr-1을 포함하는 유방암 예후 마커 및 비만 유도조성물 |
US20080108091A1 (en) * | 2006-08-07 | 2008-05-08 | Hennessy Bryan T | Proteomic Patterns of Cancer Prognostic and Predictive Signatures |
US8697373B2 (en) | 2006-10-06 | 2014-04-15 | Clarient Diagnostic Services, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
US8335360B2 (en) * | 2007-05-14 | 2012-12-18 | Historx, Inc. | Compartment segregation by pixel characterization using image data clustering |
WO2008156669A1 (en) | 2007-06-15 | 2008-12-24 | Historx, Inc. | Method and system for standardizing microscope instruments |
US20100221722A1 (en) * | 2007-06-15 | 2010-09-02 | University Of North Carolina At Chapel Hill | Methods for evaluating breast cancer prognosis |
CA2604317C (en) | 2007-08-06 | 2017-02-28 | Historx, Inc. | Methods and system for validating sample images for quantitative immunoassays |
CA2596204C (en) * | 2007-08-07 | 2019-02-26 | Historx, Inc. | Method and system for determining an optimal dilution of a reagent |
WO2009029810A1 (en) * | 2007-08-31 | 2009-03-05 | Historx, Inc. | Automatic exposure time selection for imaging tissue |
EP2034027A1 (en) * | 2007-09-04 | 2009-03-11 | Siemens Healthcare Diagnostics GmbH | Molecular markers to predict response to chemotherapy and EGFR family inhibiton by targeted strategies |
JP2010537659A (ja) * | 2007-09-07 | 2010-12-09 | ユニヴェルシテ リブル ドゥ ブリュッセル | Er−患者におけるガンの予後判定のための方法およびツール |
GB0720113D0 (en) * | 2007-10-15 | 2007-11-28 | Cambridge Cancer Diagnostics L | Diagnostic, prognostic and predictive testing for cancer |
WO2009055480A2 (en) * | 2007-10-22 | 2009-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tgf-beta gene expression signature in cancer prognosis |
WO2009089521A2 (en) * | 2008-01-10 | 2009-07-16 | Nuvera Biosciences, Inc. | Predictors for evaluating response to cancer therapy |
WO2009158620A2 (en) * | 2008-06-26 | 2009-12-30 | Dana-Farber Cancer Institute, Inc. | Signatures and determinants associated with metastasis methods of use thereof |
ES2338843B1 (es) * | 2008-07-02 | 2011-01-24 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Huella genomica de cancer de mama. |
CN102159214A (zh) | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
ES2573945T3 (es) * | 2008-09-16 | 2016-06-13 | Novartis Ag | Cuantificación reproducible de expresión de biomarcadores |
US20100124747A1 (en) * | 2008-11-03 | 2010-05-20 | University Of Southern California | Compositions and methods for diagnosis or prognosis of testicular cancer |
WO2010062705A1 (en) * | 2008-11-03 | 2010-06-03 | Quest Diagnostics Investments Incorporated | Cancer diagnosis using ki-67 |
KR101141103B1 (ko) * | 2009-12-15 | 2012-05-02 | 계명대학교 산학협력단 | 임상진단 결정 규칙 생성 방법 |
BR112012024718A2 (pt) * | 2010-03-31 | 2017-01-10 | Sividon Diagnostics Gmbh | método para a predição da recorrência de câncer da mama sob tratamento endócrino |
EP2564200B8 (en) * | 2010-04-27 | 2019-10-02 | The Regents of The University of California | Cancer biomarkers and methods of use thereof |
MY191929A (en) | 2010-06-03 | 2022-07-18 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
US9129426B2 (en) * | 2010-08-31 | 2015-09-08 | General Electric Company | Motion compensation in image processing |
FR2964744B1 (fr) * | 2010-09-10 | 2015-04-03 | Univ Versailles St Quentin En Yvelines | Test pronostic de l'evolution d'une tumeur solide par analyse d'images |
US10018631B2 (en) | 2011-03-17 | 2018-07-10 | Cernostics, Inc. | Systems and compositions for diagnosing Barrett's esophagus and methods of using the same |
WO2013010136A2 (en) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US20130096021A1 (en) * | 2011-09-27 | 2013-04-18 | Arul M. Chinnaiyan | Recurrent gene fusions in breast cancer |
US9115388B2 (en) | 2011-11-01 | 2015-08-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Gene signature for the prediction of NF-kappaB activity |
EP2773390B1 (en) * | 2011-11-03 | 2020-12-30 | Tripath Imaging, Inc. | Methods and compositions for preparing samples for immunostaining |
US8885912B2 (en) * | 2011-11-03 | 2014-11-11 | General Electric Company | Generate percentage of positive cells for biomarkers by normalizing and autothresholding the image intensity produced by immunohistochemistry technique |
WO2013159099A2 (en) * | 2012-04-20 | 2013-10-24 | Memorial Sloan-Kettering Cancer Center | Gene expression profiles associated with metastatic breast cancer |
US8737709B2 (en) * | 2012-04-30 | 2014-05-27 | General Electric Company | Systems and methods for performing correlation analysis on clinical outcome and characteristics of biological tissue |
WO2013164280A1 (en) * | 2012-04-30 | 2013-11-07 | General Electric Company | Systems and methods for analyzing biomarker co-localization in a biological tissue |
EP2877598A1 (en) | 2012-07-24 | 2015-06-03 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
US20150212087A1 (en) * | 2012-07-27 | 2015-07-30 | Centre Leon Berard | Detection of the ERalpha/Src/PI3K Complex as Predictive Marker in Breast Cancer |
JP2014123230A (ja) * | 2012-12-20 | 2014-07-03 | Sony Corp | 画像処理装置、画像処理方法、及び、プログラム |
CN103136333B (zh) * | 2013-01-29 | 2016-08-10 | 冯力新 | 一种抽象属性的量化评价分析方法 |
CN103293321B (zh) * | 2013-05-27 | 2015-05-13 | 北京大学 | 一种检测dna损伤诱导的早期核仁应激的试剂盒及其应用 |
ES2709509T3 (es) | 2013-08-12 | 2019-04-16 | Pharmacyclics Llc | Procedimientos para el tratamiento de cáncer amplificado por HER2 |
US9519823B2 (en) * | 2013-10-04 | 2016-12-13 | The University Of Manchester | Biomarker method |
US9953417B2 (en) | 2013-10-04 | 2018-04-24 | The University Of Manchester | Biomarker method |
US9785752B1 (en) * | 2014-02-25 | 2017-10-10 | Flagship Biosciences, Inc. | Method for stratifying and selecting candidates for receiving a specific therapeutic approach |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
WO2015148825A2 (en) * | 2014-03-27 | 2015-10-01 | Rong Li | Methods and compositions for evaluating breast cancer patients |
WO2015189264A1 (en) | 2014-06-10 | 2015-12-17 | Ventana Medical Systems, Inc. | Predicting breast cancer recurrence directly from image features computed from digitized immunohistopathology tissue slides |
KR20170084086A (ko) | 2014-11-17 | 2017-07-19 | 아르노 테라퓨틱스 인코포레이티드 | 오나프리스톤 연장-방출 조성물 및 방법 |
WO2016090323A1 (en) | 2014-12-05 | 2016-06-09 | Prelude, Inc. | Dcis recurrence and invasive breast cancer |
US20180040120A1 (en) * | 2014-12-29 | 2018-02-08 | Flagship Biosciences, Inc. | Methods for quantitative assessment of mononuclear cells in muscle tissue sections |
KR101765999B1 (ko) | 2015-01-21 | 2017-08-08 | 서울대학교산학협력단 | 암 바이오마커의 성능 평가 장치 및 방법 |
US10115187B2 (en) * | 2015-01-30 | 2018-10-30 | Raytheon Company | Apparatus and processes for classifying and counting corn kernels |
CA2998924A1 (en) | 2015-09-25 | 2017-03-30 | Context Biopharma Inc. | Methods of making onapristone intermediates |
US10962544B2 (en) | 2015-11-25 | 2021-03-30 | Cernostics, Inc. | Methods of predicting progression of Barrett's esophagus |
US20190113423A1 (en) * | 2015-12-02 | 2019-04-18 | Clearlight Diagnostics, LLC | Methods for preparing and analyzing tumor tissue samples for detection and monitoring of cancers |
US10548905B2 (en) | 2015-12-15 | 2020-02-04 | Context Biopharma Inc. | Amorphous onapristone compositions and methods of making the same |
CN108882902B (zh) | 2016-02-08 | 2022-08-30 | 医默观***公司 | 用于图像中对象的可视化和表征的***和方法 |
EP3430384A4 (en) * | 2016-03-14 | 2019-07-31 | Proteocyte Diagnostics Inc. | AUTOMATED METHOD FOR THE ASSESSMENT OF CANCER RISK BY TISSUE SAMPLES AND SYSTEM THEREFOR |
CA3017853A1 (en) | 2016-03-14 | 2017-09-21 | Somalogic, Inc. | Compounds and methods for the synthesis of 5-(n-protectedtryptaminocarboxyamide)-2'-deoxyuridine phosphoramidite for incorporation into a nucleic acid |
EP3446121A1 (en) * | 2016-04-20 | 2019-02-27 | Eisai Inc. | Prognosis of serous ovarian cancer using biomarkers |
US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
US11935215B2 (en) | 2017-08-07 | 2024-03-19 | Imago Systems, Inc. | System and method for the visualization and characterization of objects in images |
AU2019339508A1 (en) | 2018-09-14 | 2021-04-15 | Prelude Corporation | Method of selection for treatment of subjects at risk of invasive breast cancer |
WO2020124084A1 (en) * | 2018-12-15 | 2020-06-18 | The Brigham And Women's Hospital, Inc. | Augmented digital microscopy for lesion analysis |
EP4182480A1 (en) | 2020-07-17 | 2023-05-24 | European Molecular Biology Laboratory | Prognostic biomarkers for cancer |
WO2024148280A1 (en) | 2023-01-06 | 2024-07-11 | Ideaya Biosciences, Inc. | Treatment of er+ breast cancer comprising homologous recombination deficiency using parc inhibitor |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
WO1994000591A1 (en) * | 1992-06-26 | 1994-01-06 | Nippon Shinyaku Co., Ltd. | Monoclonal antibody, production process, antibody-producing cell, and diagnostic method |
DE69532276T2 (de) * | 1994-02-14 | 2005-02-10 | Autocyte North Carolina Llc | Automatisiertes cytologisches probenklassifizierungsverfahren |
US5989811A (en) | 1994-09-29 | 1999-11-23 | Urocor, Inc. | Sextant core biopsy predictive mechanism for non-organ confined disease status |
US5869040A (en) * | 1995-06-07 | 1999-02-09 | Biogen, Inc | Gene therapy methods and compositions |
JP2002514098A (ja) * | 1996-08-25 | 2002-05-14 | センサー インコーポレイテッド | 虹彩取得用イメージのための装置 |
US5798266A (en) * | 1996-08-27 | 1998-08-25 | K-Quay Enterprises, Llc | Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer |
EP0943095A2 (en) * | 1996-11-22 | 1999-09-22 | Shiloov Medical Technologies, Ltd. | A whole blood/mitogen assay for the early detection of a subject with cancer and kit |
JP5213202B2 (ja) * | 1998-10-28 | 2013-06-19 | バイシス・インコーポレーテツド | 細胞アレイならびに遺伝障害マーカーの検出および使用方法 |
US6960449B2 (en) * | 1999-02-10 | 2005-11-01 | Cell Works Diagnostics, Inc. | Class characterization of circulating cancer cells isolated from body fluids and methods of use |
CA2368152A1 (en) * | 1999-03-15 | 2000-09-21 | Eos Biotechnology, Inc. | Novel methods of diagnosing and treating breast cancer, compositions, and methods of screening for breast cancer modulators |
US6642009B2 (en) * | 1999-05-17 | 2003-11-04 | Cytyc Health Corporation | Isolated ductal fluid sample |
US20030087265A1 (en) * | 2000-01-21 | 2003-05-08 | Edward Sauter | Specific microarrays for breast cancer screening |
JP2004512012A (ja) * | 2000-04-04 | 2004-04-22 | メディカル リサーチ カウンシル | 細胞検出法 |
US6946484B2 (en) * | 2000-04-26 | 2005-09-20 | Cellegy Pharmaceuticals, Inc. | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
GB0011439D0 (en) * | 2000-05-12 | 2000-06-28 | Novartis Res Found | Cancer diagnosis and assays for screening |
AU2001277172A1 (en) * | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-trans protein and related reagents and methods of use thereof |
US6703204B1 (en) * | 2000-07-28 | 2004-03-09 | The Brigham & Women's Hospital, Inc. | Prognostic classification of breast cancer through determination of nucleic acid sequence expression |
DE10101792B4 (de) * | 2001-01-17 | 2004-03-18 | Vivotec Biomedical Technologies Gmbh | Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern |
US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
US7514209B2 (en) * | 2001-06-18 | 2009-04-07 | Rosetta Inpharmatics Llc | Diagnosis and prognosis of breast cancer patients |
JP3721105B2 (ja) * | 2001-08-22 | 2005-11-30 | 日本電気株式会社 | 組織検査法を利用する胃癌の切除手術後の予後検査方法 |
US7065236B2 (en) | 2001-09-19 | 2006-06-20 | Tripath Imaging, Inc. | Method for quantitative video-microscopy and associated system and computer software program product |
US6855554B2 (en) * | 2001-09-21 | 2005-02-15 | Board Of Regents, The University Of Texas Systems | Methods and compositions for detection of breast cancer |
US20040002067A1 (en) * | 2001-12-21 | 2004-01-01 | Erlander Mark G. | Breast cancer progression signatures |
US7133547B2 (en) * | 2002-01-24 | 2006-11-07 | Tripath Imaging, Inc. | Method for quantitative video-microscopy and associated system and computer software program product |
WO2003069307A2 (en) * | 2002-02-14 | 2003-08-21 | The Johns Hopkins University School Of Medicine | Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer |
US20040018525A1 (en) * | 2002-05-21 | 2004-01-29 | Bayer Aktiengesellschaft | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
US20040229299A1 (en) * | 2002-05-21 | 2004-11-18 | Badal M. Youssouf | Intracellular complexes as biomarkers |
US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
EP1613961A4 (en) * | 2003-04-01 | 2007-03-07 | Monogram Biosciences Inc | SURFACE RECEPTOR COMPLEXES AS BIOMARKERS |
CN1905876B (zh) * | 2003-11-17 | 2010-06-09 | 诺瓦提斯公司 | 二肽基肽酶iv抑制剂的用途 |
US20050221398A1 (en) * | 2004-01-16 | 2005-10-06 | Ipsogen, Sas, A Corporation Of France | Protein expression profiling and breast cancer prognosis |
WO2005071419A2 (en) * | 2004-01-16 | 2005-08-04 | Ipsogen | Protein expression profiling and breast cancer prognosis |
CN1957256B (zh) * | 2004-03-24 | 2013-01-02 | 三路影像公司 | 用于子宫颈疾病检测的方法和组合物 |
-
2005
- 2005-09-22 US US11/233,510 patent/US20060063190A1/en not_active Abandoned
- 2005-09-22 JP JP2007532688A patent/JP2008513032A/ja active Pending
- 2005-09-22 CA CA2580937A patent/CA2580937C/en active Active
- 2005-09-22 KR KR1020077009202A patent/KR20070061893A/ko not_active Application Discontinuation
- 2005-09-22 MX MX2007003502A patent/MX2007003502A/es unknown
- 2005-09-22 KR KR1020077009120A patent/KR20070068401A/ko not_active Application Discontinuation
- 2005-09-22 WO PCT/US2005/033931 patent/WO2006036726A1/en active Application Filing
- 2005-09-22 AU AU2005289728A patent/AU2005289728B2/en not_active Ceased
- 2005-09-22 EP EP05810348A patent/EP1800130B1/en active Active
- 2005-09-22 EP EP05800441A patent/EP1805676A1/en not_active Withdrawn
- 2005-09-22 US US11/233,243 patent/US7899623B2/en active Active
- 2005-09-22 BR BRPI0515581-9A patent/BRPI0515581A/pt not_active IP Right Cessation
- 2005-09-22 AT AT05810348T patent/ATE520988T1/de not_active IP Right Cessation
- 2005-09-22 AU AU2005289756A patent/AU2005289756B2/en active Active
- 2005-09-22 CA CA002580795A patent/CA2580795A1/en not_active Abandoned
- 2005-09-22 JP JP2007532659A patent/JP5184087B2/ja active Active
- 2005-09-22 BR BRPI0515562-2A patent/BRPI0515562A/pt not_active IP Right Cessation
- 2005-09-22 WO PCT/US2005/034152 patent/WO2006036788A2/en active Application Filing
-
2007
- 2007-03-20 IL IL182062A patent/IL182062A0/en unknown
- 2007-03-20 IL IL182063A patent/IL182063A0/en unknown
-
2009
- 2009-05-14 US US12/466,149 patent/US20090269856A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060078926A1 (en) | 2006-04-13 |
MX2007003502A (es) | 2007-10-10 |
ATE520988T1 (de) | 2011-09-15 |
BRPI0515581A (pt) | 2008-07-29 |
US20090269856A1 (en) | 2009-10-29 |
JP2008513032A (ja) | 2008-05-01 |
AU2005289728A1 (en) | 2006-04-06 |
EP1800130B1 (en) | 2011-08-17 |
EP1805676A1 (en) | 2007-07-11 |
WO2006036788A2 (en) | 2006-04-06 |
US20060063190A1 (en) | 2006-03-23 |
IL182062A0 (en) | 2007-07-24 |
AU2005289756A1 (en) | 2006-04-06 |
WO2006036788A3 (en) | 2006-08-17 |
AU2005289756B2 (en) | 2011-10-13 |
WO2006036726A1 (en) | 2006-04-06 |
AU2005289728B2 (en) | 2011-11-24 |
EP1800130A2 (en) | 2007-06-27 |
CA2580795A1 (en) | 2006-04-06 |
IL182063A0 (en) | 2008-04-13 |
CA2580937A1 (en) | 2006-04-06 |
JP2008513793A (ja) | 2008-05-01 |
JP5184087B2 (ja) | 2013-04-17 |
CA2580937C (en) | 2016-02-02 |
KR20070068401A (ko) | 2007-06-29 |
KR20070061893A (ko) | 2007-06-14 |
US7899623B2 (en) | 2011-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0515562A (pt) | métodos e composições para avaliação do prognóstico do cáncer de mama | |
Patschan et al. | A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma | |
Peshkin et al. | BRCA1/2 mutations and triple negative breast cancers | |
Donovan et al. | Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy | |
Lotan et al. | Molecular subtyping of clinically localized urothelial carcinoma reveals lower rates of pathological upstaging at radical cystectomy among luminal tumors | |
Glass et al. | Validation of a genomic classifier for predicting post-prostatectomy recurrence in a community based health care setting | |
MY150234A (en) | Predictive markers for ovarian cancer | |
Janda et al. | Early detection of melanoma: a consensus report from the Australian skin and skin cancer research centre melanoma screening Summit | |
Ravvaz et al. | Predicting nonmuscle invasive bladder cancer recurrence and progression in a United States population | |
Peng et al. | An expression signature at diagnosis to estimate prostate cancer patients’ overall survival | |
WO2005100999A3 (en) | Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer | |
Van den Broeck et al. | Validation of the Decipher test for predicting distant metastatic recurrence in men with high-risk nonmetastatic prostate cancer 10 years after surgery | |
MXPA06012232A (es) | Uso del patron proteogenomico del plasma para diagnostico, clasificacion, prediccion de respuesta a la terapia y comportamiento clinico, estratificacion de la terapia y monitoreo de enfermedad, en malignidades hematologicas. | |
Saldanha et al. | 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma | |
Sonpavde et al. | Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy | |
Faba et al. | High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment | |
Oderda et al. | Cell-cycle progression-score might improve the current risk assessment in newly diagnosed prostate cancer patients | |
Scarisbrick et al. | Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome | |
Sughayer et al. | Applying new Magee equations for predicting the Oncotype Dx recurrence score | |
Ibrahim et al. | Artificial intelligence-based mitosis scoring in breast cancer: Clinical application | |
Zheng et al. | Application of nomograms to predict overall and cancer-specific survival in patients with chordoma | |
Roque et al. | Bone scan index as metastatic bone disease quantifier and predictor of radium-223-dichloride biochemical response | |
Mannelli et al. | Nomograms predictive for oncological outcomes in malignant parotid tumours: recurrence and mortality rates of 228 patients from a single institution | |
Tomasini et al. | Adrenal surgery for oligometastatic tumors improves survival in selected cases | |
Mafra et al. | Cancer survival in the northwestern of São Paulo State, Brazil: A population-based study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 6A ANUIDADE. |